M32 Effect of pirfenidone on all-cause mortality (acm) and forced vital capacity (fvc) in idiopathic pulmonary fibrosis (ipf) patients with low fvc and/or low dlco: analysis of pooled data from ascend and capacity

Abstract

IntroductionThe pivotal trials of the two approved therapies in IPF, pirfenidone and nintedanib, assessed patients with protocol-defined mild to moderate disease. The effect of pirfenidone in patients with more severe...